Haemonetics Corporation HAE
NYSE
| 09/26/2026 | 06/27/2026 | 03/28/2026 | 12/27/2025 | 09/27/2025 | |
|---|---|---|---|---|---|
| Revenue | 9.30% | 5.60% | 4.76% | -2.75% | -5.27% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 9.30% | 5.60% | 4.76% | -2.75% | -5.27% |
| Cost of Revenue | 3.28% | 6.84% | 12.67% | -10.09% | -14.00% |
| Gross Profit | 13.41% | 4.78% | -0.45% | 2.93% | 1.78% |
| SG&A Expenses | 15.70% | 5.98% | 8.35% | 0.17% | -4.70% |
| Depreciation & Amortization | -6.97% | -10.43% | -7.13% | -10.61% | -8.82% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 8.43% | 5.57% | 8.44% | -6.30% | -9.53% |
| Operating Income | 12.57% | 5.70% | -13.44% | 13.42% | 15.12% |
| Income Before Tax | 22.57% | 5.32% | -140.15% | 20.15% | 14.72% |
| Income Tax Expenses | 31.37% | 30.76% | -164.69% | 22.64% | 15.89% |
| Earnings from Continuing Operations | 19.70% | -3.00% | -134.75% | 19.33% | 14.34% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 19.70% | -3.00% | -134.75% | 19.33% | 14.34% |
| EBIT | 12.57% | 5.70% | -13.44% | 13.42% | 15.12% |
| EBITDA | 8.40% | 1.89% | -10.06% | 7.39% | 9.08% |
| EPS Basic | 25.19% | 2.88% | -136.98% | 28.23% | 22.30% |
| Normalized Basic EPS | 10.69% | 10.62% | -26.78% | 27.73% | 24.83% |
| EPS Diluted | 23.46% | 2.86% | -137.05% | 28.38% | 22.73% |
| Normalized Diluted EPS | 8.57% | 10.34% | -26.36% | 28.09% | 25.48% |
| Average Basic Shares Outstanding | -4.39% | -5.72% | -6.04% | -6.95% | -6.50% |
| Average Diluted Shares Outstanding | -2.52% | -5.48% | -6.57% | -7.21% | -6.98% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |